Wudhikarn, Kitsada http://orcid.org/0000-0001-9528-8681
Perales, Miguel-Angel http://orcid.org/0000-0002-5910-4571
Article History
Received: 18 May 2022
Revised: 24 June 2022
Accepted: 30 June 2022
First Online: 15 July 2022
Competing interests
: M-AP reports honoraria from Abbvie, Allovir, Astellas, Bristol-Myers Squibb, Celgene, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, OrcaBio, Takeda, and VectivBio AG, Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune and Omeros. He has received institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. KW declares no relevant conflict of interest.
Free to read: This content has been made available to all.